Inducible gene regulation methods are indispensable in diverse biological applications, yet many of them have severe limitations in their applicability. These include inducer toxicity, a limited variety of organisms the given system can be used in, and side effects of the induction method. In this study, a novel inducible system, the , was created using a mutant ligand-binding domain of the glucocorticoid receptor (CS1/CD), used together with various genetic elements such as the Gal4 DNA-binding domain or Cre recombinase. The RuX system is shown to be capable of over 1000-fold inducibility, has flexible applications, and is offered for use in cell cultures.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630016 | PMC |
| http://dx.doi.org/10.1155/2023/7121512 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Method for measuring the transpiration resistance of fruit and vegetables.
MethodsX
December 2024
Leibniz Institute for Agricultural Engineering and Bioeconomy (ATB), Department Systems Process Engineering, Potsdam, Germany.
This investigation explores the intricate relationship between postharvest quality losses in fruit and vegetables and the dynamic interplay of transpiration and respiration activities. It underscores the profound impact of inherent produce properties and postharvest environmental conditions on transpiration, inducing changes in both external appearance and internal quality, notably wilting. Despite their common use, produce-specific transpiration coefficients encounter limitations due to diverse assumptions in calculations.
View Article and Find Full Text PDFRuxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related haemophagocytic lymphohistiocytosis.
Br J Haematol
October 2024
Hematological Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
For autoimmune disease (AD) and autoinflammatory disease (AID)-related haemophagocytic lymphohistiocytosis (HLH) (AD/AID-HLH), there is still a lack of standardized treatment. Glucocorticoids (GCs) are the main treatment currently; however, 37.9% to 61% of patients fail to achieve effective control of HLH, making it urgent to find novel treatment strategies.
View Article and Find Full Text PDFJanus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what's the current standard of care?
Expert Rev Hematol
November 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction: JAK inhibitors (JAKi) have changed the treatment paradigm of myelofibrosis (MF). Currently, 4 JAKis are approved in the US as monotherapy (mono) to treat patients with MF. JAKis are also being studied in combination (combo) with novel agents.
View Article and Find Full Text PDFEpigenetic mechanisms of osteoarthritis risk in human skeletal development.
medRxiv
May 2024
Biosciences Institute, Newcastle University, Central Parkway, Newcastle upon Tyne, United Kingdom.
The epigenome, including the methylation of cytosine bases at CG dinucleotides, is intrinsically linked to transcriptional regulation. The tight regulation of gene expression during skeletal development is essential, with ~1/500 individuals born with skeletal abnormalities. Furthermore, increasing evidence is emerging to link age-associated complex genetic musculoskeletal diseases, including osteoarthritis (OA), to developmental factors including joint shape.
View Article and Find Full Text PDFTBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Breast Cancer Res
January 2024
Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA, 02215, USA.
Background: Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) being associated with the worst survival, warranting the investigation of novel therapies. Preclinical studies implied that ruxolitinib (RUX), a JAK1/2 inhibitor, may be an effective therapy for TN-IBC.
Methods: We conducted a randomized phase II study with nested window-of-opportunity in TN-IBC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!